Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the invention relates to an aqueous ophthalmic formulation containing a chitosan salt for use as artificial tears having antimicrobial activity and to the use of a chitosan salt for preparing an aqueous ophthalmic formulation for use as artificial tears having an antimicrobial activity.
• Normal tears are a complex combination of substances which form three layers on the eye.
• a very thin outer oily layer contains lipids from the meibomina glands in the eyelid, to reduce evaporation.
• a thick middle watery layer produced by the lachrymal glands, keeps the salinity and the acidity of the tears at proper level and also carries antibodies and other immune defense agents to defend the eye against infection.
• a very thin inner mucus layer helps maintaining a stable tear film.
• Dry eye syndrome which is the decline of the quality or quantity of tears bathing the eye, can lead if untreated to scarring or uiceration of the cornea, and thus loss of vision.
• the dry eye syndrome may result of a very large range of causes such as aging, diseases and side effects of diseases, medications, contact lenses, environmental conditions, computer uses, and so one.
• Artificial tears which are available at the present time contain generally as the major component glycerine, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylalcohol or hyaluronic acid salts.
• EP-A-0,698,388 discloses an ophthalmic preparation for use as artificial tears containing hyaluronic acid salts as a viscosity thickener.
• a frequent complication of dry eye is the appearance of infections due to the reduced quantity of lysozyme, one of the natural infection-fighting components present in the tears.
• An object of the present invention is to provide an aqueous ophthalmic formulation for use as artificial tears which can be administrated to the eye in convenient drop form, and which prevents and cures infections or surinfections inherent to the treatment of dry eye by artificial tears without problems of tolerance even for a prolonged use.
• this object has been achieved as a result of the inexpected findings that an aqueous composition containing a very low concentration of chitosan salt can be useful as artificial tears having antimicrobial efficacy when administered in convenient drop form to the eye.
• Chitosan is known as a chitin derivative obtained by partial to substantial deacetylation of chitin also named poly(N-acetyl-D-glucosamine), which is a naturally occuring biopolymer found in shellfish.
• Chitosan contains free amine (-NH 2 ) groups and may be characterized as to the proportion of N-acetyl-D-glucosamine units and D-glucosamine units, and such is expressed as the degree of deacetylation of the fully acetylated polymer chitin.
• Chitosan is known to have numerous pharmaceutical activities.
• EP-A-0, 356,060 discloses compositions for use in the treatment of wounds such as dermal ulcers, said compositions containing chitosan which show a combination of antimicrobial activity and wound healing capability. Under the conditions tested, bacte ostatic activity is reported to be observed beginning with a 0.5 % concentration of chitosan malate. However, bactericidal activity is reported to be obtained only with compositions containing 10 % or more of chitosan malate.
• US-A-5, 015,632 discloses that chitosan pyrithione has an antimicrobial activity against a number of strains tested, including Staphylococcus aureus, equivalent to that of sodium pyrithione but that chitosan acetate was not effective against the strains tested.
• US-A-5,422,116 discloses that chitosan is useful for preparing a liquid ophthalmic aqueous sustained release delivery system which provides a slow and sustained release of the treating agents incorporated therein to the eye.
• a list of antibacterian agents which could be incorporated in the formulation as treating agent against infections is disclosed.
• the present invention provides an aqueous ophthalmic formulation for use as artificial tears having antimicrobial activity, said aqueous ophthalmic formulation comprising 0.05 - 3 wt/v % of a chitosan salt having a deacetylation degree of 50 - 90 % and a molecular weight of 80,000 - 5,000,000 Da, said aqueous ophthalmic formulation having a viscosity of 10 - 500 mPa.s and a physiologically acceptable pH.
• the present invention has for object the use of a chitosan salt having a deacetylation degree of 50 - 90 % and a molecular weight of 80,000 - 5,000,000 Da for the preparation of an aqueous ophthalmic formulation for use as artificial tears having antimicrobial activity, the chitosan salt being used in an amount of 0.05 - 3 wt/v % based on the total aqueous ophthalmic formulation, said aqueous ophthalmic formulation having a viscosity of 10 - 500 mPa.s and a physiologically acceptable pH.
• the present invention provides an aqueous ophthalmic formulation containing low concentration of chitosan salt for use as artificial tears having antimicrobial efficacy without further addition of an antimicrobial agent when administered in convenient drop form to the eye, which can prevent and cure infections or surinfections inherent to the treatment of dry eye by artificial tears even if unit doses are badly used as mentioned above, and which can be used without problems of tolerance even during a prolonged treatment such as for life.
• An advantage of the use of chitosan under its salt form is that an addition of diluted acids, such as hydrochloric or acetic acids, to solubilize the chitosan having free amine groups is not required in the preparation of the ophthalmic formulation.
• chitosan salt means a chitosan containing ammonium (-NH 3 + ) groups with corresponding counterions (X " ) instead of free amine (-NH 2 ) groups.
• the "degree of deacetylation" in a sample of chitosan salt means the relative amounts of N-acetyl-D-glucosamine units and D-glucosammonium salt units present in the chitosan sample, and is expressed as the degree of deacetylation of the fully acetylated polymer chitin.
• antimicrobial activity means both bactericidal and bacteriostatic activity.
• Chitosan salt as used in the present invention is a chitosan salt having a counterion X " derived from an inorganic or organic acid and having a deacetylation degree of 50 - 90 % and a weight average molecular weight of 80,000 - 5,000,000 Da.
• Chitosan salt in various forms which can be used in the present invention is commercially available or can be prepared by a process based on deacetylation of chitin until the desired deacetylation degree, e.g. as described by Roberts, G.A.F., in "Chitin chemistry", Mc Millan Press LTD, Houndmills, p.
• chitosan salts Commercial sources of chitosan salts are for example Pronova® Biopolymer, Drammen, Norway; Vanson Company, Redmond, Washington, USA; Nova Chem Limited, Armdale, Why Nova Scotia, Canada; Biosynth A.G., Staad, Switzerland; Biopolymer Engineering, Inc., St-Paul, Minnesota, USA.
• the weight average molecular weight of chitosan salt used in the present invention may be determined by size exclusion chromatography as mentioned hereafter.
• Chitosan salts of molecular weights lower than 80,000 Da are not appropriate for use in the present invention because required viscosity may be not obtained.
• Chitosan salts of molecular weights greater than 5,000,000 Da are not advantageous since they imply high manufacturing costs and also since they form very stiff gels which cannot be easily and reproducibly applied.
• the chitosan salt used in the present invention has a molecular weight of 160,000 - 580,000 Da.
• the deacetylation degree of chitosan salts may be determined by a spectrophotometric method such as described in the literature by Muzarelli, R.A. and Ricchetti, R., in Carbohydr. Polym. 5, p. 461-472, 1985 or Muzarelli, R.A. and Richetti, R. in "Chitin in Nature and Technology", Plenum Press, p. 385-388, 1986.
• Chitosan salt for use in the present invention has a deacetylation degree of 50 - 90% which means that the chitosan salt comprises 50 - 90 % of D-glucosammonium units with corresponding counterions and 50 - 10 % of N-acetyl-D-glycosamine units, respectively.
• chitosan salt as used in the present invention has a deacetylation degree of 83 % to 87 %.
• particularly preferred chitosan salts are chitosan hydrochloride and chitosan glutamate.
• the aqueous ophthalmic formulation of the present invention comprises from 0.05 to 3 wt/v % of chitosan salt.
• a formulation having a content of chitosan salt lower that 0.05 wt/v % is not appropriate for use as artificial tears having antimicrobial activity because the precomeal residence time becomes too short and the bactericidal effect becomes non-significant.
• a formulation having a content of chitosan salt greater than 3 wt/v % is not appropriate for use as artificial tears because the presence of chitosan salt at this concentration may cause undesired side-effects such as irritation and intolerance.
• the chitosan salt is used in an amount of 0.5 to 1.5 wt/v %, based on the total aqueous ophthalmic formulation.
• the aqueous ophthalmic formulation of the present invention has a viscosity of 10 - 500 mPa.s.
• An ophthalmic formulation having a viscosity lower than 10 mPa.s is not advantageous for use as artificial tears because the precomeal residence time of the formulation becomes too short.
• a formulation having a viscosity higher than 500 mPa.s is not appropriate for use as artificial tears because it forms a too stiff gel to be readily applied.
• a particularly preferred ophthalmic formulation has a viscosity of 10 to 100 mPa.s.
• the concentration of chitosan salt is adjusted according to the molecular weight and deacetylation degree of the chitosan salt used and according to the desired viscosity of the aqueous ophthalmic formulation.
• aqueous ophthalmic formulation of the present invention has a Newtonian rheological behaviour.
• the aqueous ophthalmic formulation has a physiologically acceptable pH, preferably a pH of 5.4 - 7.0.
• the osmolality of the aqueous ophthalmic formulation of the present invention ranges from 240 to 340 mosm/kg thus providing physiological acceptance.
• the aqueous ophthalmic formulation of the present invention may be prepared according to conventional techniques by solubilizing the chitosan salt in the appropriate amount in a phosphate buffer solution (PBS) pH 7.4.
• PBS phosphate buffer solution
• the aqueous ophthalmic formulation of the present invention can in particular be packaged as monodose units.
• the aqueous ophthalmic formulation of the present invention has an antimicrobial activity against all bacteria which are sensitive to chitosan, in particular gram negative strains and gram positive strains, such as E.coli and S. aureus.
• S. aureus is particularly advantageous since it is known that such strains are very resistant and cause numerous problems in hospitals. It is to be noted that S. aureus is very often implicated in eye bacterial infections (conjunctivitis).
• the aqueous ophthalmic formulation of the present invention has a very good wetting effect and a long precomeal residence time, and is very well tolerated. It is therefore appropriate to be used as artificial tears for prolonged treatment.
• the aqueous ophthalmic formulation of the present invention is particularly useful for preventing and treating infections when administered as artificial tears.
• the aqueous ophthalmic formulation of the present invention is also advantageously used as artificial tears in the treatments of dry eye syndrome, eye irritations caused by environmental conditions or contact lenses, keratoconjunctivitis sicca, Sj ⁇ gren's syndrome bacterial infections on the surface of the eye or related anterior structures caused by bacteria which are sensitive to chitosan, and in the prophylaxis of the bacterial infections in case of trauma and before or after surgery of the eye.
• aqueous ophthalmic formulation of the present invention can be used for topical administration to the eye in drop form.
• tests will now be described with reference to an example wherein chitosan hydrochloride is being used as the chitosan salt.
• the chitosan hydrochloride tested is named UPCI 110 and provided by Pronova®Biopolymer, Drammen, Norway.
• the molecular weight of the UPCI 110 tested has been determined by size exclusion chromatography, with a Waters 600 E apparatus, combined with an autosampler (Waters TM717plus) and a Waters 410 differential refractometer.
• the conditions of analysis were the following :
• 0.1 % solution of UPCI 110 in acetate buffer was injected five times.
• the molecular weight of UPCI 110 has been determined to be 160,000 Da.
• the deacetylation degree of UPCI 110 has been provided by the supplier and has been verified to be 87 % by the spectrophotometric method described in the above mentioned literature by Muzarelli, R.A. and Ricchetti, R.
• Tolerance of formulations containing UPCI 110 has been tested on rabbits and evaluated by using a confocal laser scanning ophthalmoscope (CLSO® Zeiss, Germany) modified by a set of lenses to examine the cornea instead of the retina.
• the rabbits were instillated with 25 ⁇ l of the test solution 4 times a day during 3 days. After the last instillation, the rabbits were sedated with an intramuscular injection of ketamine HCI/xylazine). Then, 25 ⁇ l of sodium fluorescein solution 0.5% in PBS were instilled in the eye to be tested. Fluorescein allows the injured areas to be selectively marked.
• the eye was then rinsed during 1 minute with a NaCI 0.9% solution. Then, the cornea was examined. Each aqueous ophthalmic solution was tested on 3 rabbits.
• Corneal lesions after topical administration of ophthalmic solutions having different concentrations are expressed in percentage of corneal fluorescent areas.
• Corneal lesions of less than 25 % are generally accepted as indicating a very good tolerance. The present results are therefore very satisfactory.
• formulations of the present invention based on chitosan hydrochloride have a precomeal residence time longer than PBS or normal saline. It is to be noted that the precomeal residence time can be increased by increasing the molecular weight or the concentration of the chitosan salt in the formulation, i.e. by increasing the viscosity of the formulation.
• E. Coli strains used in the tests were isolated from clinical specimens in the University of Geneva.
• S. aureus strains used in the tests were ATCC 25 925 obtained from the collection of Institut Pasteur (Paris, France).
• Controls were phosphate buffer solution (PBS) pH 7.4 and artificial tear commercial solution (Protagent® Unit-dose), and the volumes used were the same as the chitosan hydrochloride based solutions.
• the antimicrobial efficacy was determined twice for each bacterial strain.
• the number of bacteria present in the liquid medium(BHI) at the beginning of the test was 1.35 x 10 6 .
• the limit between the bactericidal and bacteriostatic effects is situated between concentrations of 0.005 and 0.015 % of chitosan.
• aqueous ophthalmic formulations of the present invention are given for illustrative purposes and are not intended to limit the scope of the invention.
• chitosan hydrochloride UPCI 110 as referred above, having a molecular weight of 160,000 Da and a deacetylation degree of 87 %, is solubilized in 500 ml of a phosphate buffer solution (PBS) pH 7.4, at room temperature under magnetic stirring.
• PBS phosphate buffer solution
• the resulting aqueous ophthalmic formulation contains 0.5 % of chitosan hydrochloride, has a viscosity of 10 mPa.s, a pH of 5.47, and an osmolality of 290 mosm/kg.
• chitosan hydrochloride UPCI 110 as referred above, having a molecular weight of 160,000 Da and a deacetylation degree of 87 %, is solubilized in 500 ml of a phosphate buffer solution (PBS) pH 7.4, at room temperature under magnetic stirring.
• PBS phosphate buffer solution
• the resulting aqueous ophthalmic formulation contains 1.5 % of chitosan hydrochloride, has a viscosity of 30.7 mPa.s, a pH of 5.48, and an osmolality of 290 mosm/kg.
• chitosan glutamate UPG 210 obtained from Pronova®Biopolymer, Drammen, Norway, having a molecular weight of 580,000 Da and a deacetylation degree of 83 %, is solubilized in 500 ml of a phosphate buffer solution (PBS) pH 7.4, at room temperature under magnetic stirring.
• PBS phosphate buffer solution
• the resulting aqueous ophthalmic formulation contains 1.0 % of chitosan glutamate, has a viscosity of 54.5 mPa.s, a pH of 5.48 and an osmolality of 290 mosm/kg.
• Examples 1 and 2 may be packaged either in monodose units or in appropriate containers.
• the formulations of Examples 1 , 2 and 3 may be topically administered by instillation in the eye in convenient drop form.

Priority Applications (4)

Applications Claiming Priority (1)

Publications (2)

Family

ID=11004783

Family Applications (1)

Country Status (9)

Families Citing this family (11)

Family Cites Families (3)

• 1998
  • 1998-11-20 DK DK98954658T patent/DK1128809T3/da active
  • 1998-11-20 SI SI9830746T patent/SI1128809T1/xx unknown
  • 1998-11-20 AT AT98954658T patent/ATE285751T1/de active
  • 1998-11-20 AU AU11699/99A patent/AU1169999A/en not_active Abandoned
  • 1998-11-20 EP EP98954658A patent/EP1128809B1/fr not_active Expired - Lifetime
  • 1998-11-20 WO PCT/IB1998/001886 patent/WO2000030609A1/fr active IP Right Grant
  • 1998-11-20 ES ES98954658T patent/ES2234164T3/es not_active Expired - Lifetime
  • 1998-11-20 DE DE69828451T patent/DE69828451T2/de not_active Expired - Lifetime
  • 1998-11-20 PT PT98954658T patent/PT1128809E/pt unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events